Ballad Health CVA Heart Institute cardiologist, Dr. Chris Metzger, leads national study on the effectiveness of the CGuard system developed by InspireMD ... read more about Ballad Health hosts first United States clinical trials of CGuard Embolic Protection System.
You are here
Ballad Health partners with Mayo Clinic for COVID-19 research study
Ballad Health has announced a partnership with Mayo Clinic to conduct a national coronavirus disease 2019 (COVID-19) research study.
The study will examine convalescent plasma as an experimental treatment for COVID-19, as some data indicates patients with COVID-19 might be able to fight off the virus by receiving antibodies from patients who have recovered from COVID-19.
We are now in need of donor plasma from patients who have tested positive and recovered from COVID-19 – more than 28 days out from their diagnosis and doing well, or 14 days out, asymptomatic and have been retested with a negative result.
The patients who have recovered from COVID-19 are thought to have developed antibodies to COVID-19 that might help sick patients combat their COVID-19 infections, and we want to offer this therapy. Each unit donated has the potential to help at least two patients who are currently and hospitalized with COVID-19.
Samples will be collected at Marsh Regional Blood Center in Kingsport, with plans to expand to Johnson City and Bristol soon. The blood center can be contacted at (423) 408-7500 or by visiting the Marsh website.
For up-to-date information about the COVID-19 pandemic, please visit our COVID-19 page.